Amarachi Nwankpah v. Aledade, Inc.

CourtDistrict Court, D. Maryland
DecidedDecember 12, 2025
Docket8:25-cv-01122
StatusUnknown

This text of Amarachi Nwankpah v. Aledade, Inc. (Amarachi Nwankpah v. Aledade, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Amarachi Nwankpah v. Aledade, Inc., (D. Md. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

AMARACHI NWANKPAH, *

Plaintiff, *

v. * Civ. No. DLB-25-1122

ALEDADE, INC., *

Defendant. *

MEMORANDUM OPINION Dr. Amarachi Nwankpah filed this action against her former employer, Aledade, Inc. (“Aledade”), alleging violations of federal and state anti-discrimination laws, Maryland wage laws, and Maryland common law. Aledade has moved to dismiss six of the 12 counts in Dr. Nwankpah’s amended complaint. Specifically, Aledade argues that Dr. Nwankpah’s claims for a violation of the Maryland Wage and Hour Law (“MWHL”), Md. Code Ann., Lab. & Empl. § 3- 401 et seq.; “fraud/fraudulent inducement”; promissory estoppel; unjust enrichment; intentional infliction of emotional distress (“IIED”); and intentional discrimination in violation of 42 U.S.C. § 1981a must be dismissed for failure to state a claim. For the reasons that follow, the motion is granted in part and denied in part. I. Background Dr. Nwankpah alleges the following in her amended complaint. Dr. Nwankpah is African American. ECF 8, ¶ 9. Aledade is a network of primary care organizations “that serves more than 2,400 primary care practices and community health centers across 46 states.” Id. ¶ 7. On August 19, 2022, Aledade hired Dr. Nwankpah as a Regional Medical Director. Id. ¶ 9. Two Caucasian individuals also were hired as Regional Medical Directors at the same time as Dr. Nwankpah. Id. ¶ 13. During her interview for the position, Dr. Nwankpah was told that she would be responsible only for Aledade’s North Carolina market. Id. ¶ 12. After she began working for Aledade, Dr. Nwankpah was put in charge of Aledade’s Mississippi market; this responsibility was in addition to her responsibility for overseeing the

North Carolina market. Id. Dr. Nwankpah states that “Aledade induced [her] into accepting this significant change in responsibility by promising her that she would be entitled to receive two . . . additional bonuses - one for each market - if she continued her employment.” Id. ¶ 14. Aledade represented that each bonus would be worth between $20,000 and $50,000 and that if Dr. Nwankpah worked during any part of 2022, she would be entitled to her bonuses by the end of the first quarter of 2023. Id. Dr. Nwankpah did not receive an increase in salary in exchange for assuming responsibility for the Mississippi market. Id. ¶ 15. No other Regional Medical Director was put in charge of two markets at once. Id. ¶ 13. Other Regional Medical Directors “were assigned to oversee only one . . . market each with significantly less work for essentially the same pay.” Id.

Dr. Nwankpah states that “the Mississippi market . . . was one of the most difficult markets for Regional [Medical] Directors to work with given its high turnover rate and other factors.” Id. ¶ 18. When Dr. Nwankpah was put in charge of the two markets, her workload ballooned. Id. ¶¶ 16, 19. She and her colleagues “knew it would be extremely difficult for her or anyone else to handle both these markets simultaneously due to the need for significant onboarding and the mountain of work it would entail.” Id. ¶ 19. Dr. Nwankpah also states that, due to Mississippi’s “well-known history of intense racial discrimination and persecution, which remains ongoing,” she “had concerns about working in the Mississippi market.” Id. ¶ 20. Dr. Nwankpah was supervised by Dr. Lelin Chao, an Asian woman. Id. ¶ 17. Dr. Chao in turn was supervised by Dr. Jennifer Brull, who was Caucasian. Id. ¶ 22. Dr. Nwankpah repeatedly asked Dr. Chao and Dr. Brull for support in managing her increased workload and in adjusting to her new responsibilities, but they did not provide her with meaningful support. Id. ¶¶ 17, 22. “The

only real tool” that Dr. Nwankpah received “was a 30-60-90 day plan generated by Dr. Brull that was created for [r]egional [medical] [d]irectors in charge of only one . . . market,” which Dr. Chao “confirmed . . . did not apply to Dr. Nwankpah based on her extensive workload.” Id. ¶ 23. Without her supervisors’ support, Dr. Nwankpah was “left to train and supervise herself, doing everything she could to learn from other employees to be successful.” Id. ¶ 17. Dr. Nwankpah states that other Regional Medical Directors who were not African American and had less responsibility than she did were provided with more support. Id. ¶¶ 16, 22. Dr. Chao began to “subject[ ] [Dr. Nwankpah] to unfair scrutiny . . . in a manner that was completely inconsistent with the way her counterparts and other leaders in [Aledade] were treated.” Id. ¶ 24. For instance, in November 2022, Dr. Chao “question[ed] Dr. Nwankpah on her

dedication to” Aledade after Dr. Nwankpah attended a workplace retreat virtually due to illness— even though other employees, including another Caucasian Regional Medical Director, also attended the retreat virtually but were not questioned or reprimanded in the same manner. Id. ¶¶ 25–27. Nonetheless, Dr. Chao gave Dr. Nwankpah a positive performance review the following month. Id. ¶ 30. In January 2023, Dr. Nwankpah reported “her concerns about the discriminatory treatment she had been facing from Dr. Chao” to Joshua Swann, Aledade’s vice president of diversity, equity, and inclusion. Id. ¶ 28. Swann “told Dr. Nwankpah that he was not happy with Dr. Chao’s conduct and suggested [that Dr. Nwankpah] contact Human Resources.” Id. Dr. Nwankpah did not do so because she feared that Dr. Chao would retaliate against her and “hop[ed], without much confidence, that the unfair treatment would improve.” Id. Swann’s position obligated him “to escalate Dr. Nwankpah’s reports to upper management, including Human Resources, but he failed to do so” and Dr. Nwankpah’s concerns went unaddressed. Id. ¶ 29.

In February 2023, Aledade circulated a survey asking employees to “rat[e] their experience with the [c]ompany.”1 Id. ¶ 31. The survey purported to be anonymous and confidential, and it “directly stated that the responses would not be shared with the reporting employee’s manager.” Id. In reliance on these representations, Dr. Nwankpah “felt comfortable being open and honest about the issues she was experiencing with Dr. Chao” in the survey and “specifically detailed the differential treatment and other issues she had been experiencing.” Id. However, Dr. Nwankpah’s responses were shared with Dr. Chao and Dr. Brull; in fact, hers was the only survey to be shared with a supervisor. Id. After Dr. Nwankpah’s responses were shared, “Dr. Chao became increasingly hostile and retaliatory” towards her. Id. ¶ 33. For instance, Dr. Chao “privately met with Dr. Nwankpah’s entire field team and subordinates - without any notice to Dr. Nwankpah”

and “rallied [her] team against her” while “solicit[ing] criticism of her performance and leadership behind her back.” Id. ¶ 34. Following this meeting, Dr. Nwankpah’s team began “copying Dr. Chao on all communications with Dr. Nwankpah” at Dr. Chao’s direction and began referring to Dr. Nwankpah by her first name only instead of by her honorific. Id. ¶ 35. In late February or early March 2023, Dr. Nwankpah again reported her concerns to Swann, who told her that “he believed the way Dr. Chao had been treating her was inappropriate”

1 Dr. Nwankpah states that this survey was circulated in February 2022. The Court presumes that this is a scrivener’s error and that Dr. Nwankpah meant to say February 2023 because Dr. Nwankpah alleges that she was hired in August 2022 and fired in April 2023. Thus, the only February during which Dr. Nwankpah would have been employed by Aledade was February 2023.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kolstad v. American Dental Assn.
527 U.S. 526 (Supreme Court, 1999)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Aaron Tobey v. Terri Jones
706 F.3d 379 (Fourth Circuit, 2013)
United States Ex Rel. Elms v. Accenture LLP
341 F. App'x 869 (Fourth Circuit, 2009)
Sass v. Andrew
832 A.2d 247 (Court of Special Appeals of Maryland, 2003)
Harris v. Jones
380 A.2d 611 (Court of Appeals of Maryland, 1977)
Hill v. Cross Country Settlement, LLC
936 A.2d 343 (Court of Appeals of Maryland, 2007)
Hamilton v. Ford Motor Credit Co.
502 A.2d 1057 (Court of Special Appeals of Maryland, 1986)
Pavel Enterprises, Inc. v. AS Johnson Co., Inc.
674 A.2d 521 (Court of Appeals of Maryland, 1996)
Berry & Gould v. Berry
757 A.2d 108 (Court of Appeals of Maryland, 2000)
Takacs v. Fiore
473 F. Supp. 2d 647 (D. Maryland, 2007)
Friolo v. Frankel
819 A.2d 354 (Court of Appeals of Maryland, 2003)
Arbabi v. Fred Meyers, Inc.
205 F. Supp. 2d 462 (D. Maryland, 2002)
Farasat v. Paulikas
32 F. Supp. 2d 244 (D. Maryland, 1997)
Ferdinand-Davenport v. Children's Guild
742 F. Supp. 2d 772 (D. Maryland, 2010)
Pollard v. Wawa Food Market
366 F. Supp. 2d 247 (E.D. Pennsylvania, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
Amarachi Nwankpah v. Aledade, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/amarachi-nwankpah-v-aledade-inc-mdd-2025.